Retatrutide

Retatrutide is a next-generation investigational peptide developed to target three key metabolic hormone pathways simultaneously — GLP-1, GIP, and glucagon receptors — to deliver unmatched results in weight management, metabolic control, and overall wellness support. Its unique triple-agonist mechanism is designed to optimize appetite regulation, boost energy expenditure, and improve glycemic balance more effectively than traditional single- or dual-hormone therapies.

• Substantial Weight Loss: Up to ~24% body-weight reduction in clinical studies.

• Enhanced Metabolic Health: Improved insulin sensitivity, reduced fasting glucose, and decreased HbA1c.

• Liver Health: Up to 81–86% reduction in liver fat content.

• Comprehensive Wellness: Favourable changes in adiponectin, leptin, triglycerides, and waist circumference.

• Study: 48-week, double-blind, placebo-controlled Phase 2 trial

• Results: ~22.8% weight loss (8 mg dose), ~24.2% weight loss (12 mg dose)

• ~0.9% HbA1c reduction

• Significant improvements in cardiometabolic risk factors

• Most common side effects: nausea, vomiting, diarrhea, abdominal discomfort, constipation — typically mild to moderate and

dose-dependent.

• Serious adverse events: Rare and comparable to placebo when dosing is titrated gradually.

• Ongoing monitoring recommended for pancreatitis, gallbladder events, or potential long-term effects.

• Administered as a once-weekly subcutaneous injection.

• Studied doses: 1 mg, 4 mg, 8 mg, 12 mg.

• Optimal results seen at 8 mg–12 mg with titration to improve tolerability.

• No approved dosing regimen currently exists — investigational use only.